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Percutaneous closure of ostium secundum atrial 
septal defects (ASD II) is the contemporary treatment of 
choice. It has proven to be effective and safe, with very 
low complication risk. We present two patients: a 9-year-
old boy with an 18-mm-diameter ASD II closed using the 
20-mm Cardia Ultrasept occluder and a 6-year-old girl 
with a 16-mm-diameter ASD II closed using the 20-mm 
Ultrasept occluder without any periprocedural compli-
cations. The positioning of the devices was correct and 
complete closure of the shunts was confirmed in the 
follow-up echocardiography. Patients were in routine fol-
low-up and echocardiographic examination 4 and 3 years 
after implantation respectively. The follow-up revealed 
a few streams of left-to-right shunts through the device. 
The shunts were hemodynamically significant, causing 
volume overload and right atrial and right ventricular 
enlargement. Consequently, the devices were surgical-
ly removed and the ASDs were closed with pericardial 
patches 6 and 4.5 years after implantation respectively. 
Visual inspection revealed multiple perforations in the 
left and right parts of both devices – only nitinol struts 
with small parts of the devices were covered with en-
dothelium (Figures 1 A, B). The Ultrasept occluder is in-
tended for closure of interatrial communications. It con-
sists of two discs connected with a self-centering waist 
made of a nitinol wire frame and covered with an Ivalon 
(polyvinyl alcohol – PVA) membrane (Figures 1 C, D). PVA 
is a synthetic polymer commonly used in medical devic-
es due to its biocompatibility and high water solubility 
[1]. The Ultrasept occluder is a well-proven implant with 
good midterm results. In our patients, complete closure 
of the ASDs was observed in follow-up echocardiography 
3 and 4 years after implantation with the next exam-
ination revealing significant shunts. It was probably due 
to incomplete endothelization of the device prior to the 
material’s absorption by the tissue. Similar dissolution of 
the PVA membrane has previously been reported as early 
as 1 week and as late as 2 years after implantation. Both 
options for surgical removal of the damaged device and 
surgical closure of the defect as well as percutaneous clo-
sure of leaks with the new device were used [2, 3]. Also, 
the nitinol wire frame fracture was observed in the simi-
lar Cardia Ultrasept device. Because of the risk of late or 
very late complications after percutaneous ASD closure 
patients require regular and life-long follow-up care. Any 
complication related to the device should be reported 
and analyzed to facilitate implant modification and con-
structional changes. The Cardia Ultrasept II with inter-
posed Gore-Tex patch is the modified last generation of 
Cardia devices. The new device was demonstrated to be 
safe and feasible. With the interposition of the Gore-Tex, 
it has been possible to abolish perforation of the Ivalon 
membrane as a complication. Such conclusions can be 
drawn from a study on 30 Mexican patients after atrial 
septal defect closure with no incidence of perforation at 
follow-up for 6 (range: 1–15) months [4].
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Figure 1. Cardia Ultrasept occluder, the removed device as seen from the left atrial side (A) and right atrial side (B).  
Cardia Ultrasept occluder as seen from the left atrial side (C) and right atrial side (D)
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